1. Home
  2. SNPS vs GSK Comparison

SNPS vs GSK Comparison

Compare SNPS & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNPS
  • GSK
  • Stock Information
  • Founded
  • SNPS 1986
  • GSK 1715
  • Country
  • SNPS United States
  • GSK United Kingdom
  • Employees
  • SNPS N/A
  • GSK N/A
  • Industry
  • SNPS EDP Services
  • GSK Biotechnology: Pharmaceutical Preparations
  • Sector
  • SNPS Technology
  • GSK Health Care
  • Exchange
  • SNPS Nasdaq
  • GSK Nasdaq
  • Market Cap
  • SNPS 112.2B
  • GSK 77.1B
  • IPO Year
  • SNPS 1992
  • GSK N/A
  • Fundamental
  • Price
  • SNPS $480.11
  • GSK $40.29
  • Analyst Decision
  • SNPS Buy
  • GSK Hold
  • Analyst Count
  • SNPS 15
  • GSK 2
  • Target Price
  • SNPS $578.33
  • GSK N/A
  • AVG Volume (30 Days)
  • SNPS 3.9M
  • GSK 3.7M
  • Earning Date
  • SNPS 09-09-2025
  • GSK 10-29-2025
  • Dividend Yield
  • SNPS N/A
  • GSK 4.01%
  • EPS Growth
  • SNPS 31.64
  • GSK N/A
  • EPS
  • SNPS 12.67
  • GSK 1.13
  • Revenue
  • SNPS $6,435,304,000.00
  • GSK $43,336,073,439.00
  • Revenue This Year
  • SNPS $17.72
  • GSK $5.43
  • Revenue Next Year
  • SNPS $36.32
  • GSK $5.14
  • P/E Ratio
  • SNPS $37.90
  • GSK $35.60
  • Revenue Growth
  • SNPS 8.00
  • GSK 0.59
  • 52 Week Low
  • SNPS $365.74
  • GSK $31.72
  • 52 Week High
  • SNPS $651.73
  • GSK $42.90
  • Technical
  • Relative Strength Index (RSI)
  • SNPS 40.89
  • GSK 54.22
  • Support Level
  • SNPS $416.79
  • GSK $40.03
  • Resistance Level
  • SNPS $444.19
  • GSK $40.53
  • Average True Range (ATR)
  • SNPS 19.89
  • GSK 0.58
  • MACD
  • SNPS -13.24
  • GSK -0.05
  • Stochastic Oscillator
  • SNPS 42.25
  • GSK 57.24

About SNPS Synopsys Inc.

Synopsys is a provider of electronic design automation software and intellectual property products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Synopsys' comprehensive portfolio is benefiting from a convergence of semiconductor companies moving up the stack of technologies toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.

About GSK GSK plc (Each representing two)

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Share on Social Networks: